All News

Craig Beavers discusses recent developments in hypertension management and the clinical implications of the Bax Hypertension and KARDIA-3 trials with Shelby Tungate from the UNC Eshelman School of Pharmacy.

BMS-986446 shows promise as a fast-tracked therapy for early Alzheimer disease, targeting tau protein to alter disease progression.

Recent research confirms that rheumatoid arthritis patients in remission can safely switch to the biosimilar infliximab-dyyb, offering a cost-effective treatment option.

William Van Decker, MD, discusses the key priorities of the upcoming ACC Legislative Conference, including telehealth, cardiovascular rehab, prior authorization reform, and the role of pharmacists in shaping patient-centered cardiovascular policy.

Derek Webb, PharmD, discusses RSV in older adults, highlighting symptoms, risk factors, and barriers to vaccination.

Johnson & Johnson presented new long-term data of icotrokinra from ICONIC-LEAD, along with data from ICONIC-ADVANCE indicating head-to-head superiority with standard-of-care deucravacitinib.

Datopotamab deruxtecan shows promise as a first-line treatment for metastatic triple-negative breast cancer, improving survival in nonimmunotherapy candidates.

Research highlights the effectiveness of the albuterol-budesonide combination for ensuring rapid relief and safety in patients with asthma.

Explore the evolving role of pharmacists in navigating FDA regulations and the impact of drug ads on patient care.

New results from the phase 3 HYPERION trial demonstrate reduced risks as early as the year following diagnosis of pulmonary arterial hypertension.

The approval is supported by findings from the INTEGUMENT-PED trial and the INTEGUMENT-OLE long-term extension study.

Martha Thorne discusses the operational, financial, and patient care challenges pharmacies face under the 340B rebate pilot and the need for advocacy, automation, and transparency to sustain access.

The angiopoietin-like-3-targeting treatment received an expanded indication for individuals aged 1 through 5 years, building on earlier approvals in older populations.

Derek Webb, PharmD, discusses RSV in older adults, highlighting symptoms, risk factors, and barriers to vaccination.

Recent research reveals that continuous glucose monitors (CGMs) may inaccurately overestimate blood sugar levels, potentially leading to unnecessary dietary changes for healthy individuals.

Pulmonary fibrosis was observed in many patients with severe COVID-19 in a retrospective cohort study, indicating the need for more effective care and prevention.

For American Pharmacists Month, see how recent instances of conflicting medical advice show the importance of pharmacists as trustworthy health care professionals.

A phase 3 study shows SYSA1902, a biosimilar to Stelara, is clinically equivalent for treating moderate to severe plaque psoriasis.

This is the second generic version of mifepristone to be approved by the FDA.

Investigators found inconsistencies across subgroups, but the overall efficacy and safety of pneumococcal vaccination was affirmed.

Matthew D. Clark, PharmD, highlights a pharmacist-led program that improved opioid safety in cancer care despite regulatory exemptions.

Discover how pharmacists play a crucial role in the OUD treatment process with buprenorphine, enhancing patient care and recovery outcomes.

MD Anderson's opioid stewardship program enhances patient safety and care by monitoring opioid use, addressing discrepancies, and fostering multidisciplinary collaboration in cancer treatment.

The approval was based on positive efficacy and safety indications from the IMforte clinical trial of patients with extensive-stage small cell lung cancer (SCLC).

FDA enhances oversight of drug ads using AI to ensure compliance, addressing risks and benefits in direct-to-consumer advertising.

Metabolic bariatric surgery offers greater weight loss and lower costs than GLP-1 treatments for obesity, prompting a reevaluation of treatment strategies.

Recent findings reveal that stereotactic radiation therapy (SABR) offers long-term survival outcomes comparable to surgery in patients with early non–small cell lung cancer (NSCLC).